UNBOXING MENOPAUSE
Join our campaign: Send a letter to the FDA urging them to remove the outdated, misleading “boxed warning” on local vaginal estrogen products.
It’s time for the FDA to remove the outdated, misleading “boxed warning” label on local vaginal estrogen products!
Women are not getting the treatment they need or deserve for the chronic, progressive, and highly prevalent Genitourinary Syndrome of Menopause (GSM). Symptoms include increased UTIs, urinary incontinence, vaginal dryness, and pain with intercourse.
Fortunately, there is treatment available for GSM: local vaginal estrogen, which has been deemed safe and effective in multiple studies and recommended by top menopause practitioners and numerous medical societies.
However, women and medical practitioners are deterred and needlessly scared by an outdated, misleading “boxed warning”—that overstates the risk of local vaginal estrogen products. It’s time for the FDA to remove these warnings so that women get the care they need and deserve.